NPPB and heart failure: Recently, the Soluble Guanylate Cyclase Stimulator in Heart Failure Study (in patients with LVEF <45%) trial, a randomized‐controlled, multicentre double‐blind trial to assess the tolerability and optimal dose of vericiguat in 456 patients with HFrEF, confirmed tolerability but failed to show a significant decrease in NT‐proBNP in the treatment groups (the primary endpoint).